The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How?

This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly mCRPCT (metastatic castration-resistant cancer). describes widely used Radium-223 and novel trend TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion growing PSMA-based therapy, we aim also to analyze most useful diagnostic tools patient selection treatment monitoring. We explored clinical practice research settings order clarify imaging procedures that may support management, including both patient’s therapy response monitoring, PSMA-PET/CT imaging. Further multicenter trials are needed, but better understanding strengths limitations molecular management help creating an effective therapeutic algorithm for mCRPC designing rational approach treatment.